Osteoporosis Prevention and Management

Definition & Risk Factors - Bone's Silent Sabotage

• Definition: Postmenopausal Osteoporosis: ↓ bone mass & micro-architectural deterioration, ↑ fracture risk post-menopause.
  • WHO Criteria: BMD T-score ≤ -2.5 SD.
• Common Fracture Sites: Vertebral, hip, wrist.
• Risk Factors:
  • Age >65 yrs
  • Female sex; estrogen deficiency (menopause)
  • Family Hx of osteoporosis
  • Low BMI (<18.5 kg/m²)
  • Smoking; Alcohol abuse
  • Corticosteroids (prednisolone >5mg/d, >3 mo)
  • Sedentary lifestyle
  • ↓ Ca/Vit D intake
  • 📌 Mnemonic: ACCESS - Alcohol, Corticosteroids, Calcium low, Estrogen low, Smoking, Sedentary lifestyle

⭐ Vertebral fractures: most common osteoporotic fractures, often asymptomatic.

Screening & Diagnosis - Unmasking Brittle Bones

• BMD Testing Indications:
  • All women ≥ 65 yrs.
  • Postmenopausal < 65 yrs with risk factors (e.g., prior fracture, low body weight).
  • Adults with fragility fracture.

⭐ Dual-energy X-ray absorptiometry (DXA) of hip & spine is gold standard.

• Interpreting DXA Results:
  • T-score: Compares BMD to young adult (postmenopausal women, men ≥ 50).
  • Z-score: Compares BMD to age-matched peers (premenopausal women, men < 50).
• FRAX® Tool:
  • Estimates 10-year fracture probability.
  • Key inputs: Age, BMI, fracture Hx, parental hip Fx, smoking, steroids.

Prevention Strategies - Fortifying Your Framework

• Lifestyle: Adopt healthy habits; cease smoking, limit alcohol.
• Calcium Intake: Crucial 1200 mg/day (postmenopausal). Sources: dairy, ragi, leafy greens.
• Vitamin D Supplementation: Aim for 800-1000 IU/day. Sources: sunlight, fortified foods. Aids $Ca^{2+}$ absorption.
• Exercise Regimen: Regular weight-bearing (e.g., walking) & muscle-strengthening. Improves bone density, balance; crucial fall prevention.

⭐ Adequate calcium and vitamin D intake are foundational for osteoporosis prevention and treatment, but often insufficient alone for established osteoporosis.

Pharmacological Therapy - Meds For Max Density

Indications: T-score ≤ -2.5, fragility #, high FRAX.

⭐ Bisphosphonates are typically first-line therapy for postmenopausal osteoporosis, significantly reducing vertebral and hip fracture risk.

Start["🩺 PMO Diagnosis
• Medical assessment• Confirm diagnosis"]

Risk{"📋 Risk Level
• Stratify severity• Clinical triage"}

High["💊 High Risk Rx
• Bisphosphonates• Denosumab agent"]

Severe["💊 Very High Risk
• Anabolic therapy• Seq. treatment"]

Serm["💊 Specific Needs
• SERM (Raloxifene)• Breast Ca prev."]

Start --> Risk Risk -->|High Risk| High Risk -->|Severe/Fail| Severe Risk -->|Breast CA| Serm

style Start fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8 style Risk fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style High fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534 style Severe fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534 style Serm fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534

## Monitoring & Follow-Up - Keeping Bones Strong

*   **DXA Monitoring**: Repeat **1-2 years** post-therapy start; less often if stable.
*   **Treatment Failure**: Indicated by significant ↓BMD or new fractures on therapy.
*   **Bisphosphonate Holiday**: Consider after **3-5 years** (oral) if stable & low-moderate risk.
    > ⭐ A 'bisphosphonate holiday' may be considered after **3-5 years** of oral bisphosphonate use in some patients to reduce the risk of rare long-term side effects.
*   **Ongoing Care**: Regularly reassess fracture risk & adherence.

```mermaid
%%{init: {'flowchart': {'htmlLabels': true}}}%%
flowchart TD
    Start["<b>💊 Osteoporosis Therapy</b><br><span style='display:block; text-align:left; color:#555'>• Initiate treatment</span><span style='display:block; text-align:left; color:#555'>• Baseline BMD</span>"]
    
    DXA["<b>🔬 Repeat DXA Scan</b><br><span style='display:block; text-align:left; color:#555'>• Interval 1-2 years</span><span style='display:block; text-align:left; color:#555'>• Compare to baseline</span>"]
    
    Stable["<b>📋 Assess Progress</b><br><span style='display:block; text-align:left; color:#555'>• Stable BMD density</span><span style='display:block; text-align:left; color:#555'>• Review at 3-5 yrs</span>"]
    
    Loss["<b>🩺 Treatment Failure</b><br><span style='display:block; text-align:left; color:#555'>• BMD loss or fracture</span><span style='display:block; text-align:left; color:#555'>• Check adherence</span>"]
    
    Reval["<b>💊 Switch Therapy</b><br><span style='display:block; text-align:left; color:#555'>• Secondary causes</span><span style='display:block; text-align:left; color:#555'>• New drug regimen</span>"]
    
    Holiday["<b>📋 Bispho. Holiday?</b><br><span style='display:block; text-align:left; color:#555'>• Drug free period</span><span style='display:block; text-align:left; color:#555'>• 3-5 year mark</span>"]
    
    MonitorOff["<b>👁️ Off-Therapy</b><br><span style='display:block; text-align:left; color:#555'>• Serial BMD checks</span><span style='display:block; text-align:left; color:#555'>• Clinical monitoring</span>"]
    
    Continue["<b>👁️ Continue Therapy</b><br><span style='display:block; text-align:left; color:#555'>• Maintain regimen</span><span style='display:block; text-align:left; color:#555'>• Ongoing monitoring</span>"]

    Start --> DXA
    DXA -->|Stable BMD| Stable
    DXA -->|BMD Loss| Loss
    Loss --> Reval
    Stable --> Holiday
    Holiday -->|Yes| MonitorOff
    Holiday -->|No| Continue

    style Start fill:#F1FCF5,stroke:#BEF4D8,stroke-width:1.5px,rx:12,ry:12,color:#166534
    style DXA fill:#FFF7ED,stroke:#FFEED5,stroke-width:1.5px,rx:12,ry:12,color:#C2410C
    style Stable fill:#FEF8EC,stroke:#FBECCA,stroke-width:1.5px,rx:12,ry:12,color:#854D0E
    style Loss fill:#F7F5FD,stroke:#F0EDFA,stroke-width:1.5px,rx:12,ry:12,color:#6B21A8
    style Reval fill:#F1FCF5,stroke:#BEF4D8,stroke-width:1.5px,rx:12,ry:12,color:#166534
    style Holiday fill:#FEF8EC,stroke:#FBECCA,stroke-width:1.5px,rx:12,ry:12,color:#854D0E
    style MonitorOff fill:#EEFAFF,stroke:#DAF3FF,stroke-width:1.5px,rx:12,ry:12,color:#0369A1
    style Continue fill:#EEFAFF,stroke:#DAF3FF,stroke-width:1.5px,rx:12,ry:12,color:#0369A1

High‑Yield Points - ⚡ Biggest Takeaways

• Estrogen deficiency is the primary driver of postmenopausal osteoporosis.
• DEXA scan (T-score ≤ -2.5) is the gold standard for diagnosis.
• Bisphosphonates (e.g., Alendronate) are first-line pharmacotherapy.
• Crucial: adequate Calcium (1000-1200 mg/day) & Vitamin D (800-1000 IU/day).
• FRAX tool assesses 10-year fracture probability, guiding treatment decisions.
• Teriparatide for severe osteoporosis; Raloxifene (SERM) for prevention, also reducing vertebral fracture risk.